Infections Joint Prosthetic Clinical Trial
Official title:
Impact of Rifampicin in Treatment Outcome of Cutibacterium Acnes Prosthetic Joint Infections
Cutibacterium acnes is involved in nearly 40% of shoulder prosthetic joint infections (PJI). After shoulder prothesis, C. acnes mainly affects hip prosthesis. One recent work from the Lyon (France) bone and joint infections reference center with data focusing mainly on hip and knee PJI has reported that C. acnes is the leading cause of late-onset PJI after coagulase negative staphylococci (CNS) (late acute PJI not considered). In such late-onset device-related infection, biofilm, as produced by C. acnes during PJI represents a major hurdle on the path to patient's cure. Because biofilm-associated bacteria have a slower metabolism and a lower multiplication rate than planktonic bacteria, antibiotic susceptibility can be hampered. Rifampicin is an antibiotic with low minimal bactericidal concentration against S. aureus and CNS biofilm-associated bacteria8 which significantly influence patient's outcome during staphylococci PJI.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05604157 -
Ancef Dosage in Knee Arthroplasty : Tourniquet Clinical Trial
|
N/A | |
| Not yet recruiting |
NCT06451224 -
Egyptian Arthroplasty Surgeons' Antibiotics Usage Awareness
|
||
| Enrolling by invitation |
NCT04297592 -
Antibiotic Prophylaxis in High-Risk Arthroplasty Patients
|
Phase 4 | |
| Recruiting |
NCT04620395 -
Percutaneous Punch Biopsy for Diagnosis of Septic and Aseptic Prosthetic Joint Failure
|
N/A |